{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:55:13Z","timestamp":1769100913873,"version":"3.49.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.2967\/jnumed.116.185280","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T01:25:20Z","timestamp":1489109120000},"page":"1414-1420","source":"Crossref","is-referenced-by-count":26,"title":["Role of <sup>18<\/sup>F-FDG PET\/CT in Posttreatment Evaluation of Anal Carcinoma"],"prefix":"10.2967","volume":"58","author":[{"given":"Cl\u00e9mence","family":"Houard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Pinaquy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Mesguich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Henriques de Figueiredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Cazeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Allard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hortense","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bordenave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"2021051712110286000_58.9.1414.1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1071\/SH12070","article-title":"The epidemiology of anal cancer","volume":"9","author":"Grulich","year":"2012","journal-title":"Sex Health."},{"key":"2021051712110286000_58.9.1414.2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20364"},{"key":"2021051712110286000_58.9.1414.3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25671"},{"key":"2021051712110286000_58.9.1414.4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ctrv.2011.02.003","article-title":"Chemotherapy\/chemoradiation in anal cancer: a systematic review","volume":"37","author":"Lim","year":"2011","journal-title":"Cancer Treat Rev."},{"key":"2021051712110286000_58.9.1414.5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol."},{"key":"2021051712110286000_58.9.1414.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.030"},{"key":"2021051712110286000_58.9.1414.7","doi-asserted-by":"crossref","unstructured":"Sebag-Montefiore D James R Meadows H . The pattern and timing of disease recurrence in squamous cancer of the anus: mature results from the NCRI ACT II trial [abstract]. J Clin Oncol. 2012(suppl):4029.","DOI":"10.1200\/jco.2012.30.15_suppl.4029"},{"key":"2021051712110286000_58.9.1414.8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10350-008-9361-x","article-title":"Abdominoperineal resection for anal cancer","volume":"51","author":"Mariani","year":"2008","journal-title":"Dis Colon Rectum."},{"key":"2021051712110286000_58.9.1414.9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604897"},{"key":"2021051712110286000_58.9.1414.10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00261-012-9958-3","article-title":"Anal carcinoma: FDG PET\/CT in staging, response evaluation, and follow-up","volume":"38","author":"Saboo","year":"2013","journal-title":"Abdom Imaging."},{"key":"2021051712110286000_58.9.1414.11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0046"},{"key":"2021051712110286000_58.9.1414.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.02.019"},{"key":"2021051712110286000_58.9.1414.13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11547-015-0562-9","article-title":"Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival","volume":"121","author":"Deantonio","year":"2016","journal-title":"Radiol Med (Torino)."},{"key":"2021051712110286000_58.9.1414.14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.ejrad.2016.05.009","article-title":"Metabolic tumour volume of anal carcinoma on 18FDG PET\/CT before combined radiochemotherapy is the only independent determinant of recurrence free survival","volume":"85","author":"Mohammadkhani Shali","year":"2016","journal-title":"Eur J Radiol."},{"key":"2021051712110286000_58.9.1414.15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijrobp.2007.09.005","article-title":"Tumor response and survival predicted by post-therapy FDG-PET\/CT in anal cancer","volume":"71","author":"Schwarz","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2021051712110286000_58.9.1414.16","doi-asserted-by":"crossref","unstructured":"Mistrangelo M Lesc A . PET-CT in anal cancer: indications and limits. In: Misciagna S , ed. Positron Emission Tomography\u2014Recent Developments in Instrumentation, Research and Clinical Oncological Practice. Turin, Italy: InTech; 2013:235\u2013256.","DOI":"10.5772\/57121"},{"key":"2021051712110286000_58.9.1414.17","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2016.01.004","article-title":"Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma","volume":"6","author":"Goldman","year":"2016","journal-title":"Pract Radiat Oncol."},{"key":"2021051712110286000_58.9.1414.18","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for statistical computing; 2014."},{"key":"2021051712110286000_58.9.1414.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.07.054"},{"key":"2021051712110286000_58.9.1414.20","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-010-0062-8"},{"key":"2021051712110286000_58.9.1414.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.101402"},{"key":"2021051712110286000_58.9.1414.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.10.048"},{"key":"2021051712110286000_58.9.1414.23","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.274"},{"key":"2021051712110286000_58.9.1414.24","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol."},{"key":"2021051712110286000_58.9.1414.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-010-1080-9"},{"key":"2021051712110286000_58.9.1414.26","first-page":"S131","article-title":"AIDS-related benign lymphadenopathy and malignant lymphoma: clinical aspects and virologic interactions","volume":"2","author":"Abrams","year":"1986","journal-title":"AIDS Res."},{"key":"2021051712110286000_58.9.1414.27","doi-asserted-by":"crossref","unstructured":"Glynne-Jones R Glynne-Jones R James R . Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP\/5FU in squamous cell carcinoma of the anus: results of ACT II [abstract]. J Clin Oncol. 2012(suppl):4004.","DOI":"10.1200\/jco.2012.30.15_suppl.4004"},{"key":"2021051712110286000_58.9.1414.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914"},{"key":"2021051712110286000_58.9.1414.29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25901"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.116.185280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:18:19Z","timestamp":1621282699000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.116.185280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,1]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.2967\/jnumed.116.185280"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.116.185280","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}